IGF2BP1 has been identified as an unfavorable prognostic indicator in tumors such as lung adenocarcinoma [107], endometrial cancer [42], gastric cancer [108], hepatocellular carcinoma, and serous ovarian cancer [41]. Here, IGF2BP1 is linked to endometrial cancer.